Status:
COMPLETED
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
Brief Summary
This study is an early access program of 'Nexavar post-marketing surveillance (PMS) for renal cell carcinoma (RCC) in Japan' which is a regulatory, local prospective and observational study for patien...
Eligibility Criteria
Inclusion
- Patients who received Nexavar for unresectable or advanced renal cell carcinoma
Exclusion
- Patients who are contraindicated based on the product label
Key Trial Info
Start Date :
February 27 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2016
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT01412671
Start Date
February 27 2008
End Date
February 28 2016
Last Update
June 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan